AstraZeneca receives FDA complete response letter for paediatric use of Symbicort
This article was originally published in Scrip
Executive Summary
AstraZeneca has received a US FDA complete response letter for its combination asthma therapy Symbicort (budesonide plus formoterol fumarate dihydrate) for the long-term maintenance treatment of asthma in paediatric patients aged six to 11 years.